News Releases | Investors Relation


Jan 26,2012	Notice to issue the 1^st and 2^nd convertible bonds with stock option rights and the 8^th stock options through placement to the third-party and convene the Extraordinary Shareholders Meeting on March 19^th,2012 (PDF118KB)

Jan 11,2012	Substance Patent of Nucleic Acid Delivery Technology was allowed in Japan (PDF96KB)

Dec 12,2011	Substance Patent of Therapeutic Proteins Delivery was allowed in the United States (PDF130KB)

Oct 11,2011	New Research Collaboration Agreement between NanoCarrier and LFB Biotechnologies on Recombinant Human Coagulation Factor VIIa for Hemophilia (PDF127KB)

Sep 26,2011	License and co-development agreement on Epirubicin Micelle (NC-6300) with Kowa Company, Ltd. as well as capital increase by allotting shares to Kowa (PDF154KB)

Sep 20,2011	Substance Patent of Therapeutic Proteins Delivery was approved in Japan (PDF76KB)

Sep 02,2011	A Substance Patent of "pH-Sensitive Micelle" was allowed in China (PDF116KB)

Aug 24,2011	Contribution to an Official Committee Activity regarding the Extension of a Patent Duration (PDF86KB)

Aug 22,2011	Substance patent of the Paclitaxel-micelle (NK105) was allowed in South Korea (PDF115KB)

Aug 09,2011	Research Collaboration Agreement with Kyoto University (PDF109KB)

Aug 09,2011	Substance patent of a Gene Carrier was allowed in Canada (PDF111KB)

Jul 20,2011	Commencement of Clinical Phase II of Nanoplatin^® (NC-6004) (PDF97KB)

Jul 15,2011	Option Agreement between NanoCarrier and LFB Biotechnologies (PDF161KB)

Jun 10,2011	Substance patent applications of "pH-Sensitive Micelle" and "Sensor Linked Micelle" are allowed(going to be registered) (PDF103KB)

Jun 03,2011	Substance patent of the Paclitaxel-micelle (NK105) was allowed in Canada (PDF113KB)

Jun 01,2011	Substance patent of the Paclitaxel-micelle (NK105) was allowed in Japan (PDF115KB)

May 12,2011	Financial Results for the year ended March 31, 2011 〔Japan GAAP〕 (non-consolidated) (PDF98KB)

May 10,2011	Substance patent of DACH-platin Analogue Micelle was allowed in USA (PDF78KB)

Mar 28,2011	Substance patent of Nucleic Acid Delivery Technology was registered in Japan (PDF75KB)

Mar 24,2011	Extension of Option Agreement between NanoCarrier and LFB Biotechnologies (PDF105KB)

Mar 24,2011	Termination Agreement of License and Supply Agreement for DACH-platin Analogue Micelle (PDF44KB)

Mar 16,2011	Substance patent of Nucleic Acid Delivery Technology was registered in Japan (PDF42KB)

Feb 16,2011	Research article on Nanoplatin^® (NC-6004) was published (PDF116KB)

Jan 13,2011	Process patent and formulation patent of DACH-platin Analogue Micelle were allowed (PDF115KB)

Jan 11,2011	Formulation-related patent of drug-incorporated micelle was allowed in the main Asian countries (PDF115KB)

Jan 06,2011	Notice on Publication of Research Article by Professor Kataoka, Scientific Advisor of NanoCarrier (PDF116KB)

Dec21,2010	Notice on the collaboration with National Cancer Center (PDF117KB)

Dec17,2010	Notice of issuance of new shares in rights offering (PDF19KB)

Dec10,2010	Substance patent of DACH-platin Analogue Micelle was allowed in the main countries in Asia-Oceania area (PDF84KB)

Nov19,2010	Substance patent applications of "pH-Sensitive Micelle" and "Sensor Linked Micelle" were allowed (going to be registered). (PDF145KB)

Oct 20,2010	NanoCarrier and LFB Biotechnologies Collaborate on Recombinant Human Coagulation Factor VIIa for Hemophilia (PDF197KB)

Oct 13,2010	Notice of issuance of new shares in rights offering (Corrected version) (PDF55KB) Detail of Correction due to translation error Pase2, Paragraph3. 3): 3． Background, purpose, and basis of the rights offering 3) In October 2007, we licensed the development and marketing rights worldwide excluding Japan for DACH-platin micelle (NC-4016) to Debiopharm S.A., and that has organized a phase I clinical trial is underway in Europe. However, in September 2010, Debiopharm S.A. notified us that this agreement will be terminated for strategic reasons of business strategy in Debiopharm. (the agreement will be conclude effectively terminated in March 2011). With the conclusion termination of the agreement, we will have exclusive worldwide development and marketing rights in addition to exclusive manufacturing right we have. As DACH-platin micelle is in the phase I clinical trial, from the results of pre-clinical, and possibly clinical trial, we expect license agreements on favorable terms and to quickly acquire new partners. Another phase I clinical trial is also planned in Japan and will cost about 220 million yen.

Pagetop